Drug Type Monoclonal antibody |
Synonyms ADEL Y03, ADELY03 |
Target |
Mechanism B2M inhibitors(Beta-2-microglobulin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | KR | 07 Dec 2023 | |
Fibrosis, Liver | Preclinical | KR | 07 Dec 2023 | |
Inflammation | Preclinical | KR | 07 Dec 2023 | |
Neoplasms | Preclinical | KR | 07 Dec 2023 | |
Pulmonary Fibrosis | Preclinical | KR | 07 Dec 2023 | |
Renal fibrosis | Preclinical | KR | 07 Dec 2023 | |
Well Aging | Preclinical | KR | 07 Dec 2023 |